MARKETSnap
  • Market Snapshots
    • Gainers & Losers
    • Most Active & More
    • 52-Week High/Low
    • Dividends
    • P/E Ratios
      • Large Caps
      • Absolute
      • Total Market PE
    • Stocks Performance
      • Large Caps
      • Absolute
    • Industries Performance
      • Industry
      • Sector
  • Analyze Stock
    • Analyze a stockAnalyze HELP →
    • FindStock Picks / Stock Screener
    • Value · HELPIntrinsic Value Calculator
    • Invest · HELPInvestment Case
    • Hold · HELP5-Year Outlook
  • Learn
  • Calendar
  • Investment Compounding
    Calculator
  • Investing Philosophy
  • More
    • Charts
    • Commodities
    • Currencies
    • Economic Indicators
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
HELP

HELP

Helus Pharma Inc.

$6.11
-0.67
 (-9.88%)
Exchange:  NASDAQ
Market Cap:  378.723M
Shares Outstanding:  34.803M
Delayed data
Overview
Earnings
Financials
Valuation
Chart

About The Company

Sector:  HealthcareView sector performance
Industry:  BiotechnologyView industry performance
   
CEO:  Michael I. Halstead
Full Time Employees:  100
Address: 
100 King Street West, Suite 5600
Toronto
ON
M5X 1C9
CA
Website:  https://www.helus.com
Helus Pharma Inc. operates as a clinical stage pharmaceutical company that focuses on developing therapies to treat psychiatric and neurological conditions. It develops HLP003, a deuterated psilocybin analog, which is in phase 3 clinical trial to treat major depressive disorder; and HLP004, a deuterated N, N-dimethyltryptamine, which is in phase 2 clinical trial for treating generalized anxiety disorders. The company’s preclinical product includes HLP005, a phenethylamine and tryptamine derivative to treat central nervous system. It has a strategic partnership agreement with Segal Trials to evaluate HLP003 for the adjunctive treatment of major depressive disorder; and Osmind for mental health treatments. It operates in Canada, the United States, the United Kingdom, and Ireland. The company was formerly known as Cybin Inc. and changed its name to Helus Pharma Inc. in October 2026. Helus Pharma Inc. was founded in 2019 and is headquartered in Toronto, Canada.

Click to read more…

Revenue Segmentation

🔒 You are currently logged out

Login

It’s free

Industry Peers

TICKERCOMPANYMKT CAPP/EFWD P/EROIC
HEHELP logoHELPHelus Pharma Inc.378.7M——-70.8%
PHPHAT logoPHATPhathom Pharmaceuticals, Inc.378.8M——-14.9%
RZRZLT logoRZLTRezolute, Inc.379.2M——-94.7%
EPEPRX logoEPRXEupraxia Pharmaceuticals Inc.390.2M——-53.4%
AVAVTX logoAVTXAvalo Therapeutics, Inc.390.9M——-20.9%
YMYMAB logoYMABY-mAbs Therapeutics, Inc.391.2M——-27.6%

EPS

Historical EPS and analyst estimates in one chart. Log in for the full interactive view and links to detailed estimates.

Log in to continue

Log in for the full EPS chart and links to analyst estimates.

Log in — it's free
View full analyst estimates

Earnings Call

No earnings call materials on file for this symbol yet.

Log in to continue

Log in to read the full transcript and AI-generated earnings summaries.

Log in — it's free
Income Statement
Balance Sheet
Cash Flow Statement
Analyst Estimates

Income Statement

Year202420252026
Revenue0472.270-44,684.342
Gross Profit00-44,803.575
EBITDA-78,412-142,674.729-141,557.413
Operating Income-78,836-143,147-141,677.413
Net Income-78,080-113,137-147,053.896

Log in to continue

Log in to see the income statement and 10 historical years.

Log in — it's free

(* All numbers are in thousands)

Balance Sheet

Year202420252026
Total Assets302,023258,618351,397.466
Total Liabilities10,09621,41827,111.454
Total Stockholders Equity291,927237,200323,876.803
Total Debt29100
Cash and Cash Equivalents208,992135,022220,028.548

Log in to continue

Log in to see the balance sheet and 10 historical years.

Log in — it's free

(* All numbers are in thousands)

Cash Flow Statement

Year202420252026
Operating Cash Flow-68,908-101,300-132,420.842
Capital Expenditure-710-1,966-1,364.238
Free Cash Flow-69,618-103,266-133,785.081
Net Income-78,080-113,137-147,053.896
Net Change in Cash192,359-73,97063,956.780

Log in to continue

Log in to see the cash flow statement and 10 historical years.

Log in — it's free

(* All numbers are in thousands)

Analyst Estimates

Fiscal Year2031Research AccessResearch AccessResearch AccessResearch Access
Estimated Revenue (Low)286,107.979Research AccessResearch AccessResearch AccessResearch Access
Estimated Revenue (High)1,363,632.371Research AccessResearch AccessResearch AccessResearch Access
Estimated Revenue (Avg)698,541.865Research AccessResearch AccessResearch AccessResearch Access
Estimated Ebitda (Low)156,427.375Research AccessResearch AccessResearch AccessResearch Access
Estimated Ebitda (High)316,024.424Research AccessResearch AccessResearch AccessResearch Access
Estimated Ebitda (Avg)217,514.912Research AccessResearch AccessResearch AccessResearch Access
Estimated Net Income (Low)14,615.148Research AccessResearch AccessResearch AccessResearch Access
Estimated Net Income (High)140,696.817Research AccessResearch AccessResearch AccessResearch Access
Estimated Net Income (Avg)62,874.302Research AccessResearch AccessResearch AccessResearch Access
Estimated SGA Expense (Low)32,385,885.308Research AccessResearch AccessResearch AccessResearch Access
Estimated SGA Expense (High)154,355,854.474Research AccessResearch AccessResearch AccessResearch Access
Estimated SGA Expense (Avg)79,071,184.251Research AccessResearch AccessResearch AccessResearch Access
Estimated EPS (Avg)1.810Research AccessResearch AccessResearch AccessResearch Access
Estimated EPS (High)4.040Research AccessResearch AccessResearch AccessResearch Access
Estimated EPS (Low)0.420Research AccessResearch AccessResearch AccessResearch Access
Number of Analysts (Estimated Revenue)2Research AccessResearch AccessResearch AccessResearch Access
Number of Analysts (Estimated EPS)3Research AccessResearch AccessResearch AccessResearch Access

Log in to continue

Log in with Research Access to see up to 5 years of analyst estimates.

Create a free account

(* All numbers are in thousands)

Current Key Metrics

?Revenue
 (TTM)
: 
  ?P/S
 (TTM)
: 
0
?Net Income
 (TTM)
: 
  ?P/E
 (TTM)
: 
-2.53
?Enterprise Value
 (TTM)
: 
90.911M  ?EV/FCF
 (TTM)
: 
-0.65
?Dividend Yield
 (TTM)
: 
0%  ?Payout Ratio
 (TTM)
: 
0%
?ROE
 (TTM)
: 
-74.47%  ?ROIC
 (TTM)
: 
-70.77%
?Net Debt
 (TTM)
: 
  ?Debt/Equity
 (TTM)
: 
0
?P/B
 (TTM)
: 
2.3  ?Current Ratio
 (TTM)
: 
10.97

Log in to continue

Log in to see all key valuation metrics and ratios for this symbol.

Log in — it's free

Forward P/E Ratios

?

Forward P/E (Avg EPS estimate) — log in with Research Access for high/low estimates and the interactive table.

Forward P/E 1YResearch AccessResearch AccessResearch AccessResearch Access
N/AResearch AccessResearch AccessResearch AccessResearch Access

Log in to continue

Log in with Research Access for forward P/E high/low estimates and the full multi-year table.

Create a free account

SWOT Analysis

🔒 You are currently logged out

Login

It's free

At what price to buy it? -
Intrinsic Value Calculator

Based on current fundamentals and analyst forecasts, MarketSnap estimates HELP intrinsic value between $0.19 – $0.42 per share. This depends on revenue growth, margins, and discount rate.

This is an automatic estimate. The most reliable way to know fair value for your own assumptions is to run the calculator below.


Calculate HELP Intrinsic Value

Common questions about HELP valuation

Is Helus Pharma Inc. (HELP) overvalued or undervalued right now?

MarketSnap estimates intrinsic value for Helus Pharma Inc. (HELP) using its proprietary valuation methodology, which incorporates discounted cash flow (DCF) analysis together with long-term earnings and fundamentals assumptions. By comparing intrinsic value to the current market price, long-term investors can see whether the stock screens as potentially overvalued, fairly valued, or undervalued today.

Is HELP a buy, hold, or sell for long-term investors?

MarketSnap does not give one-word “buy” or “sell” calls. Instead, it shows whether HELP trades at a premium or discount to its estimated intrinsic value, how sensitive that value is to growth and margin assumptions, and how the stock fits into a diversified, long-term portfolio so investors can make their own buy, hold, or sell decision.

What is HELP’s P/E ratio?

You can see HELP’s trailing P/E (TTM) and forward P/E estimates in the Current Key Metrics and Forward P/E Ratios sections above. The P/E ratio compares the current share price to earnings per share and helps investors gauge valuation relative to earnings.

How is intrinsic value calculated for HELP?

MarketSnap uses its own valuation framework—not a generic spreadsheet DCF alone. Future cash flows and earnings are projected, discounted, and combined with MarketSnap’s methodology so intrinsic value reflects fundamentals and long-term assumptions. You can run your own inputs and see the result using the Intrinsic Value Calculator above.

Is HELP a good long-term investment?

Whether HELP fits a long-term portfolio depends on your assumptions about growth, margins, and risk. MarketSnap provides the metrics, intrinsic value calculator, and SWOT context so you can form your own view rather than rely on a single buy/sell rating.

Research tools for Helus Pharma Inc.

  • Helus Pharma Inc. intrinsic value calculatorEstimate what the business is worth
  • Helus Pharma Inc. 5-year outlookWhat has to go right, and what could go wrong
HELP

1-day price chart preview. Log in for 1W through 5Y ranges and period tabs.

Daily snapshot

-9.88
MarketSnap

Trading Metrics:

Open: 6.63   Previous Close: 6.78
Day Low: 6.06   Day High: 6.73
Year Low: 3.76   Year High: 15.15
Price Avg 50: 10.78   Price Avg 200: 7.8
Volume: 2.502M   Average Volume: 1.877M

Log in to continue

Log in for multi-period charts (1W–5Y), period tabs, and the same layout as members.

Log in — it's free
See in Nexus

Relevant news

Helus Pharma Reports Second Quarter Fiscal 2027 Financial Results and Recent Business Highlights
16-11-2026 06:00
Helus Pharma Reports Second Quarter Fiscal 2027 Financial Results and Recent Business Highlights
Helus Pharma Announces Results of Annual and Special Meeting of Shareholders and Effective Date for Legal Name Change
22-09-2026 17:00
Helus Pharma Announces Results of Annual and Special Meeting of Shareholders and Effective Date for Legal Name Change

DISCLAIMER: The stock market data provided on this website is for informational purposes only and is not intended for trading purposes. While we strive to provide accurate and timely information, we cannot guarantee that the information is accurate at the moment it is received or that it will continue to be accurate in the future. We are not responsible for any actions taken based on the information provided on this website. Always consult with a licensed financial professional before making any investment decisions.
Terms of Service

Copyright © 2025 MarketSnap. All rights reserved.

Pricing

How MarketSnap works

What’s new

Contact Us

Privacy Policy

Cookie Policy

Terms of Service

Hover Image
MARKETSnap

Market

🇺🇸 United States

Language

    • Gainers & Losers
    • Most Active & More
    • 52-Week High/Low
    • Dividends
      • Large Caps
      • Absolute
      • Total Market PE
      • Large Caps
      • Absolute
      • Industry
      • Sector
    • Analyze a stockAnalyze HELP →
    • FindStock Picks / Stock Screener
    • Value · HELPIntrinsic Value Calculator
    • Invest · HELPInvestment Case
    • Hold · HELP5-Year Outlook
  • Learn
  • Calendar
  • Investment Compounding Calculator
    • Charts
    • Commodities
    • Currencies
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
  • Investing Philosophy
  • Nexus
    • Recent Activity
      • Overview
      • My Valuations
      • My Investment Journal
      • Watchlists & Portfolio
    • Plans
    • Settings
    • Public profile ↗
  • Log in
  • Log out

Media

Watch Listen Read
Ask MarketSnap AI

MarketSnap AI Assistant

Uses MarketSnap data and this page

Ready

🔒 You are currently logged out

Login

It's free

MarketSnap Assistant · Tips
    MarketSnap

    Welcome to MarketSnap

    The AI-powered workspace for stock pickers.

    Continue with Google Continue with email

    Already a member? Sign in

    Find stocks·Value them·Build the case·Journal decisions·Track what changes

    Free to join. No card needed. Privacy Policy

    Create your free MarketSnap account Continue with Google
    Chat with us MarketSnap support · account, plans, settings, help
    How MarketSnap works

    The conversation above goes to the MarketSnap team with your message. We reply by e-mail.